Larvol Delta - Ascletis-Announces-Initiation-of-Phase-I-Study-in-US-for-Oral-Amylin-Receptor-Peptide-Agonist-ASC36-for-the-Treatment-of-Obesity

ASC36o - Ascletis

https://www.prnewswire.com/news-releases/ascletis-announces-initiation-of-phase-i-study-in-us-for-oral-amylin-receptor-peptide-agonist-asc36-for-the-treatment-of-obesity-302872005.html

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next